newsfilter
← Latest News
GlobeNewswire·

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDITopline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch